Colorectal cancer (CRC), the second deadliest cancer globally, is closely tied to gut microbiota, opening doors for early detection and treatment. This review of 45 studies (2018-2024) highlights microbial biomarkers like Fusobacterium nucleatum, Bacteroides fragilis, and Parvimonas micra, with strong diagnostic accuracy (AUC >80%) across populations. Techniques like 16S rRNA sequencing, metagenomics, and shotgun sequencing revealed these links. Gut-based diagnostics offer a non-invasive, cost-effective alternative to colonoscopy and FIT for spotting early CRC and precancerous lesions. Yet, regional microbial differences and inconsistent methods-sample processing and sequencing-hinder comparability. Standardizing approaches and exploring fungi and viruses are key to unlocking microbiota's full potential in CRC prevention, diagnosis, and therapy.
Upadhyay et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: